The Patterson Analysis

Taboola's expanded OPPO deal isn't just another partnership. It's a strategic push into mobile's most valuable, and contested, digital territory.

With a new name and an external manager, Neostellar Capital is pivoting hard into AI, pouring millions into the tech's backbone. Is this the new model?

With its Q2 earnings on deck, Camden Property Trust’s performance offers a crucial look into the health of the multifamily housing market and its strategic shifts.

Leeward Renewable Energy's 725 MW Oklahoma solar portfolio is more than clean power for Google; it’s a case study in meeting digital demand with grid-scale execution.

Trey Rome's EY award celebrates Home Tax Solutions' rapid growth. But does it solve a crisis or capitalize on it? An analysis of a financial lifeline.

Command Investigations' acquisition of CoventBridge's insurance arm creates the largest US firm, but the real story is its blueprint for tech-driven dominance.

With €33M in fresh capital, Cyllene Therapeutics is advancing a novel gene therapy for bladder disease. We analyze the tech, the investors, and the plan.

Associated Capital Group's rising book value isn't just a number. It's a signal of a focused strategy executing in a dynamic alternative investment market.

Precinmac's acquisition of Advance Mfg. is more than a purchase; it's a calculated move to build a one-stop shop for mission-critical components.

Montreal's Salutt Inc. launches Ready to Date, betting its 'Love Compass' can fix a broken dating scene. But can it overcome the user density paradox?

While 30,000 union hotel workers celebrate a landmark contract, staff at two Times Square hotels picket for a living wage, backed by the city's top brass.

As BNL preps its Q2 report, its industrial pivot and build-to-suit success face a tough macroeconomic climate. We analyze the key metrics beyond the headlines.

General Motors' H1 2026 sales crown isn't just a headline. It's a case study in a dual-engine strategy that perfectly meets the Canadian market where it is.

The recent funding for Luxonis isn't just another AI investment. It’s a validation of edge computing, where intelligent machines see and act in the real world.

West's $112.5M sale of its 3.5mL device to AbbVie isn't a retreat. It's a strategic pivot to dominate the high-growth, large-volume drug delivery market.

Beyond the glitter, Canada's 2027 Eurovision entry is a calculated move. We analyze the steep costs, logistical hurdles, and immense economic potential.

New imaging data provides the first evidence that a drug-app combo for Parkinson's can induce physical changes in the brain, linking digital therapy to better outcomes.

The FDA approved Orca Bio's revolutionary cell therapy, promising better outcomes for cancer patients. But the real test lies beyond the science.

Ford's new partnership with Hueler offers employees a lifetime income option, a landmark move that could redefine corporate retirement benefits across America.

Amidst digital disruption, Oconee Federal's leadership shuffle isn't just a personnel change. It's a deliberate strategy for resilience and local relevance.